δ-Tocopherol Reduces Lipid Accumulation in Niemann-Pick Type C1 and Wolman Cholesterol Storage Disorders

Received for publication, February 29, 2012, and in revised form, September 28, 2012 Published, JBC Papers in Press, October 3, 2012, DOI 10.1074/jbc.M112.357707

Miao Xu 1,2, Ke Liu 3, Manju Swaroop 4, Forbes D. Porter 5, Rohini Sidhu 6, Sally Finkes 7, Daniel S. Ory 8, Juan J. Marugan 1, Jingbo Xiao 1, Noel Southall 1, William J. Pavan 9, Cristin Davidson 10, Steven U. Walkley 11, Alan T. Remaley 12, Ulrich Baxa 13, Wei Sun 14, John C. McKew 15, Christopher P. Austin 16, and Wei Zheng 17

From the 1National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland 20892, the 2Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver NICHD, National Institutes of Health, Bethesda, Maryland 20892, the 3Diabetic Cardiovascular Disease Center, Washington University School of Medicine, St. Louis, Missouri 63110, the 4Genetic Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, the 5Sidney Weisner Laboratory of Genetic Neurological Disease, Rose F. Kennedy Center, Albert Einstein College of Medicine, Bronx, New York 10461, the 6Laboratory of Lipoprotein Metabolism, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, the 7Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China, and the 8Electron Microscopy Laboratory, NCI, National Institutes of Health, Bethesda, Maryland 20892

Background: Niemann-Pick disease type C and Wolman diseases are caused by mutations in genes responsible for intracellular cholesterol processing and trafficking.

Results: δ-Tocopherol reduces lysosomal accumulation of cholesterol and other lipids potentially through enhancement of lysosomal exocytosis.

Conclusion: δ-Tocopherol is a novel lead compound for drug development to treat lysosomal storage diseases.

Significance: Lysosomal exocytosis may represent a new drug target broadly applicable to lysosomal storage diseases.

Niemann-Pick disease type C (NPC) and Wolman disease are two members of a family of storage disorders caused by mutations of genes encoding lysosomal proteins. Deficiency in function of either the NPC1 or NPC2 protein in NPC disease or lysosomal acid lipase in Wolman disease results in defective cell membrane trafficking. Lysosomal accumulation of cholesterol and enlarged lysosomes are shared phenotypic characteristics of both NPC and Wolman cells. Utilizing a phenotypic screen of an approved drug collection, we found that δ-tocopherol effectively reduced lysosomal cholesterol accumulation, decreased lysosomal volume, increased cholesterol efflux, and alleviated pathological phenotypes in both NPC1 and Wolman fibroblasts. Reduction of these abnormalities may be mediated by a δ-tocopherol-induced intracellular Ca2+ response and subsequent enhancement of lysosomal exocytosis. Consistent with a general mechanism for reduction of lysosomal lipid accumulation, we also found that δ-tocopherol reduces pathological phenotypes in patient fibroblasts from other lysosomal storage diseases, including NPC2, Batten (ceroid lipofuscinosis, neuronal 2, CLN2), Fabry, Farber, Niemann–Pick disease type A, Sanfilippo type B (mucopolysaccharidosis type IIIB, MPSIIIB), and Tay–Sachs. Our data suggest that regulated exocytosis may represent a potential therapeutic target for reduction of lysosomal storage in this class of diseases.

Niemann-Pick disease type C (NPC) 3 is caused by mutations in either the NPC1 or NPC2 gene, encoding two distinct lysosomal cholesterol-binding proteins (1, 2). The NPC cellular phenotype is characterized by lysosomal accumulation of unesterified cholesterol and other lipids, resulting from impaired cholesterol export from the late endosomal and lysosomal compartments (2, 3). Wolman disease is caused by mutations in the gene encoding lysosomal acid lipase (LAL). Deficiency of LAL function results in two distinct disease phenotypes that accumulate both cholesteryl ester and triglycerides. The early onset form is known as Wolman disease, and the late onset form is known as cholesteryl ester storage disease (3, 4). Enlarged lysosomes are a common cellular phenotype for both NPC and Wolman diseases.

Cholesterol is an essential component of cellular membranes and is central to maintaining both membrane integrity and fluidity as well as regulating membrane protein function, cell signaling, and ion permeability (5). In addition, cholesterol is the precursor molecule for synthesis of cellular components such as bile acids, oxysterols, and steroid hormones. Cholesterol homeostasis is tightly regulated at both the cellular and whole-
Reducing Storage in Lysosomal Diseases through Exocytosis

body levels (6). Although the homeostasis of serum and tissue cholesterol has been well defined, many details of intracellular cholesterol regulation and trafficking are yet to be elucidated. Esterified cholesterol contained in low density lipoprotein (LDL) enters a cell via endocytosis. Upon LDL entry into the late endosome/lysosome, LAL hydrolyzes fatty acyl chains from cholesteryl esters to liberate unesterified cholesterol that is transported out of the late endosome/lysosome involving NPC1 and NPC2 proteins (6–8). The precise mechanism and pathway of cholesterol trafficking from the lysosome remain unclear, although it has been established that unesterified cholesterol moves to the endoplasmic reticulum for re-esterification or utilization by the cell and to the trans-Golgi network and/or plasma membrane for efflux from the cell (5, 9).

Currently, there are no Food and Drug Administration-approved therapies for either NPC disease or Wolman disease. However, miglustat, originally approved as a substrate reduction drug for Gaucher disease, has been approved in the European Union for the treatment of NPC1 disease by the European Agency for the Evaluation of Medicinal Products. Therapeutic strategies that have been explored include reduction of lysosomal lipid burden, augmentation of mutant protein expression, or replacement of mutant proteins in lysosome (10). Enzyme replacement therapy, which has been successfully used to treat selected lysosomal storage diseases, was studied in the mouse model of Wolman disease but is not clinically approved (11). A protein replacement therapy, similar to enzyme replacement therapy, would in theory be possible for NPC2 disease, but it is not feasible for NPC1 disease because NPC1 is an integral membrane protein. A phenotypic screen of a compound collection recently identified compounds that reduced filipin staining in NPC1 fibroblasts (12), and several laboratories have reported lead compounds, including 2-hydroxypropyl-β-cyclodextrin and histone deacetylase inhibitors, that reduce cholesterol accumulation (12–15). A recent report revealed that cyclodextrin’s mechanism of action to reduce cholesterol accumulation in NPC1 mutant cells is through induction of exocytosis (16). Here we report the identification of δ-tocopherol (δ-T) in a phenotypic screen of an approved drug library that significantly reduces lysosomal cholesterol accumulation in NPC1 fibroblasts. Following δ-T treatment, the enlarged acidic endosomal/lysosome compartment was dramatically reduced, and the pathological phenotype of NPC1 cells, as determined by ultrastructural analysis, was alleviated. Similar effects of δ-T were also observed in Wolman fibroblasts. The mechanism of action for δ-T was linked to increase in cytosolic Ca²⁺, correction of the lysosomal Ca²⁺ deficiency, and enhancement of lysosomal exocytosis. The effect of δ-T also extended to patient-derived fibroblasts from other lysosomal storage diseases, including Batten (CLN2), Fabry, Farber, Niemann-Pick disease type A, NPC2, Sanfilippo type B (MPS IIIB), and Tay-Sachs. The results indicate that the enhancement of lysosomal exocytosis may represent a new therapeutic strategy for drug development that may be widely applicable to lysosomal storage diseases.

EXPERIMENTAL PROCEDURES

Materials—Hoechst and LysoTracker Red dye were purchased from Invitrogen. Filipin dye was obtained from Sigma-Aldrich. α-Tocopherol and δ-tocopherol were purchased from Sigma-Aldrich and purified by HPLC to a purity greater than 99%. β-Tocopherol (racemic), α-tocotrienol, β-tocotrienol, and γ-tocotrienol were obtained from Sigma-Aldrich in analytical standard grade (purity ≥97%). γ-Tocopherol and δ-tocotrienol were purchased from ChromaDex (Irvine, CA) in vitamin reference standard grade (purity >96%). The 96-well, 384-well, and 1536-well plates were purchased from Greiner Bio-One (Monroe, NC). Human skin fibroblast cell lines (supplemental Table S1) were purchased from the Coriell Cell Repository (Camden, NJ), including control cell line (GM05659), NPC1 (GM03123), NPC2 (GM17910), Wolman (GM11851), Batten (GM16445), Farber (GM20015), Fabry (GM00107), Niemann-Pick disease type A (GM16195), Sanfilippo type B (GM02552), and Tay-Sachs (GM00221). The GM03123 fibroblasts were utilized mainly in the NPC1 experiments unless specifically indicated. The NPC25 (c.2979dupA, p.N701K) skin fibroblast line was derived from an NPC1 patient evaluated under an NICHD, National Institutes of Health, Institutional Review Board-approved clinical protocol and obtained with consent.

Cell Culture—Both human fibroblasts and baby hamster kidney (BHK) cells were cultured in DMEM (Invitrogen, catalog no. 11995-040) supplemented with 10% fetal bovine serum (FBS), 100 unit/ml penicillin, and 100 μg/ml streptomycin in a humidified incubator with 5% CO₂ at 37 °C.

Approved Drug Collection—A collection of 2816 approved drugs that were dissolved in DMSO solution as 10 mM stock solution were set up as described previously (17). The compounds were serially diluted 1:5 in 384-well plates for seven concentrations and formatted into 1536-well plates at 5 μM/well as the compound source plates. In the primary screen, 23 nl of compounds in DMSO solution was transferred using a Pintool station (Klaypsys, San Diego, CA) to 1536-well assay plates containing 5 μl/well cell culture medium. The final concentrations of compounds ranged from 1.32 nM to 46 μM.

Amplex-Red Cholesterol Assay—Total cholesterol in patient cells was measured by the Amplex-Red cholesterol assay kit (Invitrogen). The unesterified cholesterol was determined using the same kit without the enzyme acid lipase. Esterified cholesterol was determined as the difference between the total and unesterified cholesterol values. The cells were seeded in black, tissue culture-treated 1536-well plates at 800 cells/well in 5 μl of medium by a Multidrop Combi dispenser (Thermo Scientific, Waltham, MA) and cultured for 24 h. The assay plates were added with 23 nl/well compound DMSO solution using a Pintool station (Klaypsys, San Diego, CA) and cultured for 3 days. The cells were washed twice using a centrifugation method in which the inverted plates were placed on a stack of paper towels and centrifuged at 800 rpm for 1 min followed by the addition of 7 μl/well PBS (added gently with a 45° angled liquid dispenser (Klaypsys)). The cholesterol assay mixture from the kit was added at 2.5 μl/well and incubated for 1 h at 37 °C. The resulting fluorescence intensity was measured with...
Reducing Storage in Lysosomal Diseases through Exocytosis

Cholesterol Analysis by Liquid Chromatography-Mass Spectrometry (LC-MS)—Cell pellets were collected from 100-mm dishes and washed once with 10 ml of PBS. Proteins were assayed using the BCA kit (Sigma-Aldrich), and lipids were extracted by a modified Bligh and Dyer procedure (18) from the cells. Internal standards were added based on protein concentration that included D7-cholesterol and 17:0 cholesteryl ester (Avanti Polar Lipids, Inc). The lipid extract was derivatized to convert cholesterol and its ester into acetate for facilitating ionization using a direct infusion mass spectrometric assay. The derivatization was performed by treating the dried crude lipid extract with solutions of 1 M acetic acid with 1 M DMAP (4-Dimethylaminopyridine) in chloroform and 1 M EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) in chloroform at 50 °C for 2 h. The derivatized product was extracted with hexane and analyzed by a direct infusion mass spectrometric assay with 5% ammonium hydroxide for facilitating ionization.

A triple-quadrupole mass spectrometer equipped with an electrospray was used for analysis of lipids in positive mode. Cholesterol and cholesteryl esters were detected by a neutral loss scan of 213 (collision energy, 50 V), neutral loss scan of 77 (collision energy, 14 V), and precursor ion scan of m/z 369 (collision energy, 14 V), respectively. Data processing of mass spectrometric analyses, including ion peak selection, data transfer, peak intensity comparison, and quantification, was conducted using self-programmed Microsoft Excel macros (19).

Cytotoxicity Assay—In an initial experiment, we found that commercially available vitamin E isomers were cytotoxic at concentrations required for their pharmacological effect. The ATP content assay kit (Promega or PerkinElmer Life Sciences) was applied to monitor the compound cytotoxicity. Cells were seeded in white solid 96- or 1536-well plates and treated with compounds as described above for the cholesterol assay. On the day of the experiment, 3 µl/well assay mixture (prepared according to the manufacturer’s instructions) was added to the assay plates, followed by incubation at room temperature for 10 min. The luminescence signal was determined in the luminescence mode of a Tecan multifunction plate reader.

Filipin Staining—Cells were seeded at 1500 cells/well in 100 µl of medium in black/clear bottom tissue culture-treated 96-well plates and cultured for 24 h. After the addition of compound solution, the plates were cultured for 3 days. The cells were washed twice with PBS and fixed by 100 µl/well 3.2% formaldehyde at room temperature for 30 min. After washing with PBS two times, the cells were stained with 100 µl/well 50 ng/ml filipin (freshly dissolved in DMSO at 10 mg/ml and then diluted in PBS) at room temperature for 1 h. The plates were stored at 4 °C after washing two times with PBS before the imaging analysis. On the day of the imaging experiment, cells were stained with 100 µl/well 2 µM CellMask-Red dye (Invitrogen, catalog no. H32711) in PBS at room temperature for 1 h. The plates were imaged using an Incell2000 automated fluorescence plate imaging reader (GE Healthcare) with a ×20 or ×40 objective. A DAPI filter set (excitation = 360 ± 20 nm, and emission = 460 ± 20 nm) and TRITC filter set (excitation = 545 ± 20 nm, and emission = 593 ± 20 nm) were used to visualize filipin and CellMask staining, respectively.

Nile Red Staining—The cells were cultured and treated as described above. On the day of the experiment, cells were washed two times with PBS and live-stained with 1 µM Nile Red dye solution (prepared in cell culture medium) at 100 µl/well, followed by an incubation at 37 °C for 10 min. After washing twice with PBS, the cells were fixed in 3.2% paraformaldehyde in PBS at 100 µl/well for 1 h at room temperature. The nuclear staining was carried out by an addition of 100 µl/well 1 µg/ml Hoechst 33342 (Invitrogen) in PBS and incubation at room temperature for 30 min. The plate was washed twice with PBS, and the images were measured in an Incell2000 imaging plate reader with an FITC filter set (excitation = 480 ± 20 nm, emission = 535 ± 36 nm) for the neutral lipids (cholesteryl esters and triglycerides) and a DAPI filter set for Hoechst nuclear staining.

BODIPY-lactosylceramide (BODIPY-LacCer) Staining—The cells in a 96-well assay plate were prepared as described above, incubated with 100 µl/well BODIPY-LacCer dye (Invitrogen, catalog no. B-34402) in 1% FBS DMEM, and incubated at 37 °C for 1 h, followed by plate washing with HEPES-buffered minimal essential medium (13.8 mM HEPES, 137 mM NaCl, 5.4 mM KCl, 2 mM glutamine, 0.4 mM KH₂PO₄, 0.18 mM Na₂HPO₄, 1 × minimum essential medium vitamins, and 1 × minimum essential medium amino acids at pH 7.4). The cells were rinsed with cold HEPES-buffered minimal essential medium containing 5% fatty acid-free BSA and back-exchanged at 11 °C six times over 60 min as described previously (20). Images were immediately taken in the InCell2000 imaging plate reader with the DAPI filter set.

LysoTracker dye staining—The assay was optimized to visualize the enlarged lysosomes by applying an appropriate concentration of LysoTracker dye in which the control cells exhibited minimal staining while the NPC1 or other disease cells showed significant staining. The cells were cultured and treated as described above. On the day of the experiment, cells were live-stained with 100 µl/well 50 nM LysoTracker Red DND-99 dye (Invitrogen, catalog no. L-7528) in medium at 37 °C for 1 h followed by plate washing twice with PBS. The plate was used for image analysis of live cell staining or was fixed in 100 µl/well 3.2% formaldehyde for 1 h and washed twice with PBS. The nuclear staining was performed by an addition of 100 µl/well 1 µg/ml Hoechst 33342 (Invitrogen) in PBS and incubation at room temperature for 30 min. After washing twice with PBS, the plates were stored at 4 °C until imaging analysis. A DAPI filter set and TRITC filter set in the Incell2000 imaging plate reader were used to visualize Hoechst nuclear staining and LysoTracker staining, respectively.

Electron Microscopy—Fibroblast cells were seeded in 6-well plates in 5 ml of medium at 150,000 cells/well and cultured for 1 day in the presence or absence of compounds. Cells were fixed in 2% glutaraldehyde, 0.1 M cacodylate buffer, pH 7.2, for 1 h at room temperature and then stored at 4 °C until transmission electron microscopy analysis was performed. The cells were postfixed in 1% osmium tetroxide in the same buffer for 1 h and stained en bloc with 0.5% uranyl acetate in 0.1 M acetate buffer, pH 4.2. The cells were then dehydrated in graded ethanol solu-
Reducing Storage in Lysosomal Diseases through Exocytosis

Intracellular and Lysosomal Ca$^{2+}$ Measurements—Intracellular cytosolic Ca$^{2+}$ concentration was measured fluoscently using a Fluo-8 dye kit (ATT Bioquest, Sunnyvale, CA) as described previously. Briefly, fibroblasts were cultured at 2500 cell/well in 20 μl of medium in black/clear bottom 384-well plates for 24 h at 37 °C. The calcium dye mixture was added at 20 μl/well and incubated at 37 °C for 30 min followed by room temperature for 30 min. The plates were then placed into a fluorescence kinetic plate reader (μCell, Hamamatsu, Hamamatsu City, Japan). The basal fluorescence intensity was recorded 10 times at 1 Hz for 10 s, and the compound (δ-T or α-T) was then added at 20 μl/well inside the instrument followed by an additional reading at 1 Hz for 5 min. The results were normalized to the average basal fluorescence intensity in a ratio, and the peak response (maximum) was used for the result calculation. The lysosomal Ca$^{2+}$ induced by Gly-Phe β-naphthylamide (GPN) was measured similarly as that for cytosolic Ca$^{2+}$, except 200 nM GPN was added instead of δ-T or α-T after the measurement of basal fluorescence intensity that released lysosomal Ca$^{2+}$.

Endocytosis and Lysosomal pH Measurement—Endocytosis was measured using a fluorescence-labeled dextran dye (pHrodoTM dextran; catalogue no. P10361, Invitrogen) that enters cells through endocytosis. This dye emits fluorescent signal at the acidic pH while exhibiting a minimal fluorescence signal at neutral pH. The fibroblasts in 96-well plates were treated with 40 μM δ-T or 80 μM α-T for 24 h and incubated with 20 mg/ml pHrodo dye for 16 h. The live cell imaging was carried out after a cell wash with PBS with an excitation of 560 nm and emission of 590 nm. Chlorpromazine, a known inhibitor of endocytosis, was used as a positive control (final concentration of 5 μg/ml). The lysosomal pH was determined using a fluorescent LysoSensor dextran dye (catalogue no. L-22460, Invitrogen) that emits strongly at 530 nm in an acidic pH environment and at 450 nm in neutral pH. The fibroblasts in 96-well plates were treated with 40 μM δ-T for 24 h and incubated with the pH indicator dye for 16 h. The images were taken using InCell2000 (GE Healthcare) with an excitation of 360 nm, emission-1 of 530, and emission-2 of 450 nm.

Measurement of β-Hexosaminidase (HEXB) Release—Fibroblasts were cultured in 24-well plates at 30,000 cells/well in 0.4 ml of medium for 1 day at 37 °C. After being washed twice with assay buffer (DMEM with 2 mM D-mannose 6-phosphate sodium salt), the cells with 0.4 ml/well assay buffer were incubated at 37 °C with 0.2 ml/well compound in assay buffer. At the 5, 10, 20, 30, and 40 min time points, 30 μl of assay buffer from each well in the 24-well plate were aliquoted into a 96-well black plate. The rest of the assay buffer in the 24-well plate was discarded, followed by the addition of 0.6 ml of 1% Triton X-100 in distilled H$_2$O to lyse the cells. After incubation at 37 °C for 30 min, 6 μl/well cell lysate were added to the 96-well plate with 24 μl of assay buffer, followed by 90 μl/well 2.25 mM HEXB substrate, 4-methylumbelliferyl N-acetyl-β-D-glucosaminide (Sigma-Aldrich, catalog no. M2133), in a 25 mM citric acid buffer at pH 4.5. The 96-well plate was then measured in the Tecan fluorescence plate reader (excitation = 365 ± 20 nm, and emission = 460 ± 20 nm) after a 1-h incubation at 37 °C and the addition of 100 μl/well stop solution (1 M glycine and 1 M NaOH at pH 10.5).

Data Analysis and Statistical Analysis—The compound library screen data were analyzed using software developed internally at the National Institutes of Health Chemical Genomics Center. Concentration-response curves were analyzed, and EC$_{50}$ values (mean ± S.D.) were calculated using Prism software (GraphPad, Inc., San Diego, CA). Results in figures are expressed as the mean of triplicates ± S.D. The statistical significance of differences was determined by a two-tailed
single-factor analysis or variance or Student’s t test. A p value of ≤0.05 was considered significant.

RESULTS

High Throughput Screen and Identification of Cholesterol Reduction Activity of \[\text{H}9254\]-T—Skin fibroblasts derived from NPC1 patients demonstrate profound and reproducible cholesterol accumulation in late endosomes and lysosomes and, therefore, provide a robust cellular model of NPC1 disease (12, 16). Using a phenotypic screen of 2816 approved drugs with a biochemical assay to measure unesterified cholesterol, \[\text{H}9254\]-T was identified as a lead compound that dramatically reduced cellular cholesterol accumulation in NPC1 fibroblasts. \[\text{H}9254\]-T is one of eight components in natural vitamin E that consists of a mixture of four tocopherols and four tocotrienols. All eight isomers reduced unesterified cholesterol and cholesteryl ester accumulation in NPC1 and NPC2 fibroblasts (supplemental Fig. S1A). Cholesterol accumulation in NPC1 fibroblasts was not affected by lovastatin, an inhibitor of cellular cholesterol synthesis; by either vitamin C or \[\text{N}\]-acetylcysteine, classical antioxidants; or by vitamin K, one of the other lipid soluble vitamins (supplemental Fig. S1B). The cholesterol-reducing effect of \[\text{H}9254\]-T in NPC1 cells was confirmed by LC-MS analysis (Fig. 1B). In addition to the reduction of unesterified cholesterol, cholesteryl esters were also reduced in the NPC1 cells after the treatment with \[\text{H}9254\]-T (Fig. 1C). To assess the spec-
Reducing Storage in Lysosomal Diseases through Exocytosis

A. Filipin staining (red: filipin; green: CellMask)

B. Nile-red staining (cyan: nile-red; blue: Hoechst 33342)

C. Bodipy-LacCer staining

FIGURE 2. δ-T and α-T reduced cholesterol accumulation phenotypes in NPC1 and Wolman fibroblasts. Filipin staining of unesterified cholesterol was reduced in NPC1 cells (A), and Nile Red staining of neutral lipids (cholesterol ester and triglyceride) was decreased in Wolman fibroblasts (B) by 40 μM δ-T or 80 μM α-T. The filipin-stained cells were co-stained with CellMask, a plasma membrane dye. C, mistrafﬁcking of BODIPY-LacCer in NPC1 fibroblasts was corrected by 40 μM δ-T.

The mixed lipid storage phenotype results in a marked enlargement of lysosomes in the NPC1 and Wolman fibroblasts. Therefore, we next determined whether the enlarged lysosomes in these cells could be reduced by the treatment with δ-T. LysoTracker, a probe that stains the intracellular acidic compartment, has been used to visualize the enlarged endolysosomal compartment in NPC1 cells (20). We found increased LysoTracker staining in both NPC1 and Wolman cells by 40 μM δ-T or 80 μM α-T. The LysoTracker Red staining images were merged with Hoechst nuclei dye staining. B, electron micrographs of thin sections of NPC1 and Wolman fibroblasts were compared with control fibroblasts. The inset in the untreated NPC1 fibroblast shows in detail the lamellated and osmophilic structures in lysosomes (bar, 1 μm) that were signiﬁcantly reduced by the treatment with 40 μM δ-T. In the untreated Wolman fibroblasts, the white arrowheads mark the typical elongated and cleft-shaped lipid droplets in lysosomes that were alleviated after the treatment with 40 μM δ-T.

δ-T reduces lysosomal size and corrects ultrastructural pathology of NPC1 and Wolman cells—Filipin is a ﬂuorescent antibiotic that binds to unesterified cholesterol and is commonly used in the diagnosis of NPC1 disease (12, 16, 23). Treatment of NPC1 ﬁbroblasts with either 40 μM δ-T or 80 μM α-T signiﬁcantly reduced unesteriﬁed cholesterol storage (Fig. 2A), a cellular phenotypic hallmark of NPC1 disease, thus conﬁrming the biochemical ﬁndings. Likewise, treatment of Wolman cells with these two compounds signiﬁcantly reduced staining with Nile Red (Fig. 2B), a dye used to detect nonpolar lipids, including cholesterol ester and triglyceride (24), consistent with the observed reduction of cholesteryl ester accumulation. In addition to accumulation of unesteriﬁed cholesterol, NPC1 ﬁbroblasts exhibit lysosomal storage of other lipids, including lactosylceramide (20). Thus, we examined whether the altered trafﬁcking of a ﬂuorescent lactosylceramide analog, BODIPY-LacCer, could be corrected by δ-T treatment. After treatment with 40 μM δ-T, BODIPY-LacCer staining in the NPC1 ﬁbroblasts was dramatically reduced, approaching normal levels (Fig. 2C). These results suggest that the reduction of lysosomal cholesterol accumulation by δ-T may also help to correct the defective trafﬁcking of other lipids in NPC1 cells.

δ-T increases [3H] cholesterol efflux—To investigate the mechanism of action of δ-T, we analyzed its effect on the expression of the NPC1 protein and other proteins involved in cholesterol homeostasis. We found that the protein levels of...
Reducing Storage in Lysosomal Diseases through Exocytosis

NPC1, 3-hydroxy-3-methylglutaryl-CoA reductase (the rate-limiting enzyme in cholesterol synthesis), and ABCA1 (a sterol transporter) were also not altered by δ-T treatment in NPC1 fibroblasts (supplemental Fig. S4). Taken together, these data indicate that the effect of δ-T is probably not mediated by a change in either de novo cholesterol synthesis or the major transporter involved in cholesterol efflux.

We then examined the effect of tocopherol on [3H]cholesterol efflux in BHK cells that express ABCA1 at basal level and a BHK cell line with overexpression of ABCA1. We found that 40 µM δ-T or 80 µM α-T increased the efflux of [3H]cholesterol in BHK cells from 9.0% to 32.1 or 27.6%, respectively (Fig. 4A). In the ABCA1-overexpressing cells, [3H]cholesterol efflux at the basal level was much higher than that in the parental cells. Treatment with 40 µM δ-T or 80 µM α-T was able to further increase [3H]cholesterol efflux in the ABCA1-overexpressing cells (Fig. 4A). A similar increase in [3H]cholesterol efflux was also observed in cells overexpressing ABCG1 and SR-B1 (supplemental Fig. S5). These results suggest that increased cholesterol efflux by δ-T may not be mediated by activation of a specific cholesterol efflux pathway but rather by increasing the general cholesterol efflux through diverse cellular pathways (27).

δ-T Increases Intracellular Ca²⁺ Concentration and Ameliorates Lysosomal Calcium Deficiency in NPC1 Cells—Increase in the concentration of intracellular Ca²⁺, an important second messenger, triggers a variety of cellular responses, including
Reducing Storage in Lysosomal Diseases through Exocytosis

In NPC1 fibroblasts, there is a dysregulation of calcium homeostasis, as evidenced by lysosomal Ca\(^{2+}\) deficiency (20). Treatments that compensate for loss of lysosomal Ca\(^{2+}\) (e.g. curcumin) have been reported to reduce cholesterol storage in NPC1 cells (20). To explore whether \(\delta\)-T may similarly exert its effects through changes in intracellular Ca\(^{2+}\), we measured cytosolic calcium levels in both NPC1 and Wolman cells following the treatment with \(\delta\)-T. We found that \(\delta\)-T stimulated a transient increase of cytosolic Ca\(^{2+}\) in both NPC1 and Wolman fibroblasts as well as in control fibroblasts (Fig. 4, B, D, and E). In addition, the intracellular Ca\(^{2+}\) response to \(\delta\)-T was independent of extracellular Ca\(^{2+}\). The staining in fibroblasts derived from patients with six other diseases—lipid accumulation in the lysosome and enlargement of lysosome size in affected cells are common features of more than 50 lysosomal storage diseases caused by genetic mutations of genes generally encoding lysosomal proteins (28). Despite the heterogeneity in cellular phenotypes among these diseases, lysosomal exocytosis has recently emerged as a new drug target for the potential treatment of these storage disorders (29, 30). Based on the data for both NPC1 and Wolman cells, we hypothesized that the pharmacological effect of \(\delta\)-T on the intracellular Ca\(^{2+}\) and lysosomal exocytosis is a general mechanism for elimination of lysosomal storage. To test this hypothesis, we measured the ability of \(\delta\)-T to decrease acidic lysosomal compartment size as determined by LysoTracker staining in fibroblasts derived from patients with six other diseases. Lysosomal storage in these fibroblasts consists of ceroid/lipofuscin in Batten (CLN2), globotriaosylceramide in Fabry, ceramide in Faber, sphingomyelin in Niemann-Pick disease type A, partially degraded heparan sulfate in Sanfilippo type B, and GM2 ganglioside in Tay-Sachs (supplemental Table S1). Whereas untreated fibroblasts showed increased LysoTracker staining, indicating the enlarged lysosomes (Fig. 6, A and B), treatment with \(40 \mu M\) \(\delta\)-T significantly reduced the LysoTracker staining in all six fibroblast cell lines studied (Fig. 6, A and B). The reduction of acidic cellular compartments by \(\delta\)-T treatment is consistent with decreased intracellular storage that was confirmed by alleviation of the ultrastructural pathology (Fig. 6, C and D). Thus, the amelioration of lysosomal pathology by \(\delta\)-T, initially demonstrated in NPC1 and Wolman cells, can be generalized to other lysosomal storage diseases.

**DISCUSSION**

Exocytosis is a housekeeping function responsible for the secretion of hormones, cytokines, and neurotransmitter in secretory cells. In response to a transient increase of cytosolic Ca\(^{2+}\), secretory vesicles move toward the plasma membrane, fuse with the membrane, and then expel the luminal contents into the external cellular environment. Exocytosis in nonsecretory cells plays an important role in plasma membrane repair (31), bone resorption (30), cycling/recycling proteins to plasma membrane (32), pathogen invasion (33), neurite outgrowth (34), and cellular clearance (29, 35). Lysosomes, which are the most important exocytic organelle in nonsecretory cells, release their contents in response to a transient rise in cytosolic Ca\(^{2+}\) or ionomycin (29). A recent paper reported that lysosomal exocytosis is regulated by the BHLH-leucine zipper transcription factor EB, and overexpression of transcription factor EB reduces the storage materials in cell-based disease models (30). Regulated exocytosis may be operative in vivo because lysosomal contents have been found in extracellular fluids, blood, and urine in certain patients with lysosomal storage diseases.
Reducing Storage in Lysosomal Diseases through Exocytosis

Though targeting lysosomal exocytosis may be a useful strategy to mitigate the lysosomal burden in storage diseases.

In this study, we show that δ-T, a minor vitamin E species, appears to exert its effect in NPC1 and Wolman fibroblasts through stimulation of lysosomal exocytosis. Translating these cell-based results to the in vivo use in animal models and patients poses a challenge with respect to its unfavorable pharmacokinetics. In comparison with α-T, which is present at 20–40 μM in human plasma, the highest among eight vitamin E isoforms, the δ-T plasma concentration in humans is <1 μM (36–39). Contributing to the low plasma concentration of δ-T is its rapid oxidation by the P450 enzyme CYP4F2 (40). The brain concentration of δ-T in mice was under 1 μM after a 4-week treatment with 1.67 g/kg of diet/day δ-T (49). By contrast, α-T, unique among the vitamin E isoforms, is stabilized in plasma by α-tocopherol transfer protein (41). Nonetheless, α-T is far less potent than δ-T in reducing storage in NPC1 and Wolman fibroblasts and, even with a dietary supplement, may not reach the required plasma concentration for this pharmacological effect (36, 38). In the Npc1<sup>−/−</sup> mouse model, treatment with α-T provided a functional benefit, although it did not prolong survival (42). This could be due to low plasma and tissue concentrations of α-T in the mouse that are insufficient for the activity of cholesterol reduction. Therefore, the insufficient therapeutic concentrations in plasma and brain limit the use of δ-T and α-T in the animal model study as well as in clinical use to treat patients. To explore the potential effect of δ-T in vivo, chemical optimization of its pharmacokinetic properties will be required.

Although the antioxidant capacity of vitamin E is frequently thought to be its primary biological function, a number of non-antioxidant functions have been proposed. These include regulation of enzyme function, cell signaling, cell proliferation, and neuroprotection (43, 44). Vitamin E contains a chromanol ring with a hydroxyl group that is responsible for its antioxidant effect and a 13-carbon hydrophobic phytol side chain that inserts into the plasma membrane (45). α-T, the major vitamin E isofrom in human plasma, prevents apoptosis induced by 7-ketocholesterol, one of the cholesterol oxidation products in neuronal cells that is markedly increased in NPC1 disease (46).
Reducing Storage in Lysosomal Diseases through Exocytosis

![FIGURE 6. Effect of δ-T on ultrastructural pathology in lysosomal storage disorder fibroblasts. Treatment with 40 μM δ-T reduced lysosomal size and corrected lysosomal inclusions in patient fibroblasts of Batten (CLN2), Fabry, Farber, Niemann-Pick disease type A, Sanfilippo type B (MPS IIIB), and Tay-Sachs diseases. Shown are images of LysoTracker staining in the absence (A) or presence (B) of 40 μM δ-T treatment. LysoTracker Red staining was significantly reduced after the treatment with δ-T, consistent with a decrease of the acidic compartment size. Electron micrographs of patient fibroblasts in the absence (C) or presence (D) of δ-T (bar, 2 μm in the main panels and 500 nm in the insets). Typical large osmiophilic, mono- and multinuclear multilamellar bodies are observed in Niemann-Pick disease type A (NPA), Tay-Sachs, and Farber disease cells; similar but smaller and usually multinuclear multilamellar bodies are observed in Batten (CLN2), Sanfilippo type B (MPS IIIB), and Farber disease cells (see insets for detail). The pathological phenotypes in the ultrastructure were significantly alleviated after the treatment with 40 μM δ-T in all of these six types of patient fibroblasts.](image_url)

α-T has also been shown to stimulate mast cell degranulation, a secretory form of exocytosis (47). This effect of α-T was not mediated by an up-regulation of genes for proteins involved in vesicular transport (e.g. Nsf, Cplx2, Snap23, and Stx3) but through the direct interaction of α-T with the plasma membrane (47). The pretreatment requirement of α-T for these reported pharmacological effects may be explained by the time necessary for the incorporation of α-T molecules into the plasma membrane and for the subsequent transfer of incorporated α-T molecules to other cellular organelles and compartments.

A specific target protein for δ-T has not been found or implicated. In lysosomal storage diseases, the accumulation of lipids in lysosomes impairs cellular lipid trafficking, which could directly impact plasma membrane fluidity and dynamics. It is possible that the incorporation of δ-T in the plasma membrane and the subsequent alteration of membrane physical status, such as lipid fluidity, plays a critical role in the effect of δ-T on reduction of cholesterol and other lipid in the lysosome. The increase of intracellular Ca²⁺ and subsequent lysosomal exocytosis by δ-T support a mechanism of action mediated through the favorable change in membrane physical status. Thus, further studies on membrane biophysics and the function of membrane protein as affected by δ-T are necessary to elucidate the precise mechanism of action.

Based on the above data, we have proposed a model for the pharmacological effect of δ-T on the reduction of lipid accumulation in cells from patients with lysosomal storage diseases. Under normal conditions, cellular cholesterol derived from either LDL endocytosis or de novo synthesis is mobilized from lysosomes through a LAL-NPC2-NPC1-dependent pathway for distribution to the trans-Golgi and endoplasmic reticulum. We hypothesized that a minor, low flux cholesterol trafficking pathway, such as lysosomal exocytosis, may also exist because the cholesterol accumulation in NPC1 cells can be corrected following culture in lipoprotein-deficient serum for 5–6 days (48). Deficiency in function of the NPC1 protein disrupts the LAL-NPC2-NPC1-dependent pathway for cholesterol trafficking, resulting in impaired cholesterol efflux and lysosomal accumulation of cholesterol and other lipids. When the NPC1-deficient cells are treated with a high concentration of δ-T, the enhanced lysosomal exocytosis reduces lysosomal accumulation of cholesterol and other lipids, although the defect in the LAL-NPC2-NPC1-dependent pathway is not corrected. However, given the complexity of its mechanism of action, other intracellular pathways may be involved in the vitamin E function that merit further study.

In conclusion, we have demonstrated that δ-T reduces cholesterol accumulation and alleviates cellular phenotypes in NPC1 and Wolman cells. Our data suggest that the pharmacological effect of δ-T may be mediated by stimulating an increase in cytosolic Ca²⁺ that enhances lysosomal exocytosis. This mechanism appears to be independent of either the mutant enzyme or the storage material because we found that δ-T alleviated the lysosomal storage phenotype in other fibroblasts derived from patients with Batten (CLN2), Fabry, Farber, Niemann-Pick disease type A, Sanfilippo type B (MPS IIIB), and Tay-Sachs diseases. Although utilization of δ-T directly as a therapeutic agent is at present limited by its inability to achieve adequate plasma and brain concentrations in both animals and humans, structure optimization to improve its pharmacokinetic properties and increase its plasma and tissue concentrations could lead to the development of a new class of drugs for the treatment of lysosomal storage diseases.

Acknowledgments—We thank Support of Accelerated Research for Niemann-Pick Disease Type C (SOAR-NPC) for fostering a collaborative research environment and stimulating discussion. Mass spectrometry analysis was performed in the Washington University Metabolomics Facility, supported by National Institutes of Health Grant P60 DK020579. We thank Dr. Yiannis A. Ioannou (Mount Sinai School of Medicine) for technical assistance with the exocytosis assays and Ferri Soheilian and Christina Burks for assistance with electron microscopy.
of tocopherols and tocotrienols on their \( \alpha \)-oxidation by tocopherol-\( \alpha \)-hydroxylase. J. Lipid Res. 48, 1090–1098

Reducing Storage in Lysosomal Diseases through Exocytosis